Travis Mickle - KemPharm Chairman
| KMPHDelisted Stock | USD 5.81 0.02 0.34% |
Chairman
Dr. Travis C. Mickle, Ph.D., serves as Chairman of the Board, President, Chief Executive Officer of KemPharm, Inc. Dr. Mickle is a cofounder of our company and has served as a member of our board of directors since our inception in 2006 and chairman of our board of directors since November 2014. Dr. Mickle served as our president and chief scientific officer from 2006 to October 2010, and has served as our president and chief executive officer since October 2010. Prior to founding our company, Dr. Mickle spent five years with New River Pharmaceuticals, a specialty pharmaceutical company, where he was a senior research scientist from 2001 to 2002, the director of chemistry from 2002 to 2003 and the director of drug discovery and CMC from 2003 to 2005 since 2014.
| Age | 50 |
| Tenure | 10 years |
| Professional Marks | Ph.D |
| Phone | 321 939 3416 |
| Web | https://kempharm.com |
KemPharm Management Efficiency
The company has return on total asset (ROA) of (0.0897) % which means that it has lost $0.0897 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3124) %, meaning that it created substantial loss on money invested by shareholders. KemPharm's management efficiency ratios could be used to measure how well KemPharm manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 16.16 M in liabilities with Debt to Equity (D/E) ratio of 0.16, which may suggest the company is not taking enough advantage from borrowing. KemPharm has a current ratio of 11.97, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist KemPharm until it has trouble settling it off, either with new capital or with free cash flow. So, KemPharm's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like KemPharm sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for KemPharm to invest in growth at high rates of return. When we think about KemPharm's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 6 records | CHAIRMAN Age | ||
| Eric Silagy | Nextera Energy | 58 | |
| Glenn Vangolen | Western Midstream Partners | 61 | |
| Kevin Kabat | NiSource | 63 | |
| Gale Klappa | WEC Energy Group | 73 | |
| Michael Pruitt | Fresh Grapes LLC | 63 | |
| James Robo | Nextera Energy | 58 | |
Management Performance
| Return On Equity | -0.31 | |||
| Return On Asset | -0.0897 |
KemPharm Leadership Team
Elected by the shareholders, the KemPharm's board of directors comprises two types of representatives: KemPharm inside directors who are chosen from within the company, and outside directors, selected externally and held independent of KemPharm. The board's role is to monitor KemPharm's management team and ensure that shareholders' interests are well served. KemPharm's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, KemPharm's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christal MA, CoFounder Devel | ||
| Timothy CPA, VP Controller | ||
| Sven Guenther, Executive Vice President -Research and Development | ||
| LaDuane CPA, S CFO | ||
| Andrew Barrett, VP Affairs | ||
| Travis Mickle, Founder, Chairman, CEO and President and Member of Scientific and Medical Advisory Board | ||
| Nichol Ochsner, VP Communications | ||
| Richard Pascoe, Lead Independent Director |
KemPharm Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is KemPharm a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.31 | |||
| Return On Asset | -0.0897 | |||
| Operating Margin | (1.72) % | |||
| Current Valuation | 97.06 M | |||
| Shares Outstanding | 34.5 M | |||
| Shares Owned By Insiders | 10.29 % | |||
| Shares Owned By Institutions | 17.68 % | |||
| Number Of Shares Shorted | 1.37 M | |||
| Price To Earning | 17.87 X | |||
| Price To Book | 1.69 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards KemPharm in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, KemPharm's short interest history, or implied volatility extrapolated from KemPharm options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Other Consideration for investing in KemPharm Stock
If you are still planning to invest in KemPharm check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the KemPharm's history and understand the potential risks before investing.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |